Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study
Jun Liang,Huayong Zhang,Bingzhu Hua,Hong Wang,Liwei Lu,Songtao Shi,Yayi Hou,Xiaofeng Zeng,Gary S. Gilkeson,Lingyun Sun +9 more
Reads0
Chats0
TLDR
Allogeneic MSCT in patients with refractory lupus resulted in amelioration of disease activity, improvement in serological markers and stabilisation of renal function, and MSCT appears beneficial in treatment of patients with SLE refracted to conventional treatment options.Abstract:
Objective To determine the safety and efficacy of allogeneic mesenchymal stem cell transplantation (MSCT) in refractory systemic lupus erythematosus (SLE). Methods A total of 15 patients with persistently active SLE underwent MSCT. Outcome was evaluated by changes in the SLE disease activity index (SLEDAI), serological features (anti-nuclear antibodies and anti-double-stranded DNA (anti-dsDNA)), renal function and percentage of peripheral blood regulatory T cells. Results From 11 March 2007 to 4 November 2008, 15 patients with persistently active SLE were enrolled and underwent MSCT. The mean follow-up period was 17.2±9.5 months. A total of 13 patients have been followed for more than 12 months. All patients clinically improved following treatment with mesenchymal stem cells with a marked decrease in the SLEDAI score and 24 h proteinuria. At 12-month follow-up, SLEDAI scores decreased from 12.2±3.3 to 3.2±2.8 and proteinuria decreased from 2505.0±1323.9 to 858.0±800.7 mg/24 h (all p Conclusion Allogeneic MSCT in patients with refractory lupus resulted in amelioration of disease activity, improvement in serological markers and stabilisation of renal function. MSCT appears beneficial in treatment of patients with SLE refractory to conventional treatment options.read more
Citations
More filters
Journal ArticleDOI
Clinical Trials with Mesenchymal Stem Cells: An Update:
TL;DR: Clinical trials using MSCs for representative diseases, including hematological disease, graft-versus-host disease, organ transplantation, diabetes, inflammatory diseases, and diseases in the liver, kidney, and lung are analyzed, as well as cardiovascular, bone and cartilage, neurological, and autoimmune diseases.
Journal ArticleDOI
Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial
Joshua M. Hare,Joel E. Fishman,Gary Gerstenblith,Darcy L. Velazquez,Juan P. Zambrano,Viky Y Suncion,Melissa Tracy,Eduard Ghersin,Peter V. Johnston,Jeffrey A. Brinker,Elayne Breton,Janice Davis-Sproul,Ivonne Hernandez Schulman,Ivonne Hernandez Schulman,John J. Byrnes,Adam Mendizabal,Maureen H. Lowery,Didier Rouy,Peter A. Altman,Cheryl Wong Po Foo,Phillip Ruiz,Alexandra Amador,José Paulo da Silva,Ian McNiece,Ian McNiece,Alan W. Heldman +25 more
TL;DR: In this early-stage study of patients with ICM, transendocardial injection of allogeneic and autologous MSCs without a placebo control were both associated with low rates of treatment-emergent SAEs, including immunologic reactions.
Journal ArticleDOI
Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials
Manoj M. Lalu,Lauralyn McIntyre,Lauralyn McIntyre,Christina Pugliese,Dean Fergusson,Brent W. Winston,John C. Marshall,John Granton,Duncan J. Stewart,Duncan J. Stewart +9 more
TL;DR: Based on the current clinical trials, MSC therapy appears safe, however, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs.
Journal ArticleDOI
Mesenchymal stem cells and immunomodulation: current status and future prospects
Fei Gao,Sm M. Chiu,Dal A. L. Motan,Zhao Zhang,L. Chen,Hong-Lin Ji,Hf-F. Tse,Qinf-Ling Fu,Qizhou Lian +8 more
TL;DR: The preclinical and clinical studies of MSCs from different adult tissues are summarized, the current hurdles to their use are discussed, and the future development of pluripotent stem cell-derived M SCs are proposed as an approach to immunomodulation therapy.
Journal ArticleDOI
Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells
TL;DR: Despite the minor differences between these MSC populations, ASCs seem to be as effective as BM-MSCs in clinical application, and, in some cases, may be better suited than BM- MSCs.
References
More filters
Journal ArticleDOI
Multilineage Potential of Adult Human Mesenchymal Stem Cells
Mark F. Pittenger,Alastair Morgan Mackay,Stephen C. Beck,Rama K. Jaiswal,Robin Douglas,Joseph D. Mosca,Mark Aaron Moorman,Donald William Jr. Ward Road Simonetti,Stewart Craig,Daniel R. Marshak +9 more
TL;DR: Adult stem cells isolated from marrow aspirates of volunteer donors could be induced to differentiate exclusively into the adipocytic, chondrocytic, or osteocytic lineages.
Journal ArticleDOI
Pluripotency of mesenchymal stem cells derived from adult marrow
Yuehua Jiang,Balkrishna N. Jahagirdar,R. Lee Reinhardt,Robert E. Schwartz,C. Dirk Keene,Xilma R. Ortiz-Gonzalez,Morayma Reyes,Todd Lenvik,Troy C. Lund,Mark Blackstad,Jingbo Du,Sara Aldrich,Aaron Lisberg,Walter C. Low,David A. Largaespada,Catherine M. Verfaillie +15 more
TL;DR: It is reported here that cells co-purifying with mesenchymal stem cells—termed here multipotent adult progenitor cells or MAPCs—differentiate, at the single cell level, not only into meschymal cells, but also cells with visceral mesoderm, neuroectoderm and endoderm characteristics in vitro.
Journal ArticleDOI
Human mesenchymal stem cells modulate allogeneic immune cell responses
TL;DR: Insight is offered into the interactions between allogeneic MSCs and immune cells and mechanisms likely involved with the in vivo MSC-mediated induction of tolerance that could be therapeutic for reduction of GVHD, rejection, and modulation of inflammation.
Journal ArticleDOI
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.
Craig L. Bennett,Jacinda R. Christie,Fred Ramsdell,Mary E. Brunkow,Polly J. Ferguson,Luke Whitesell,Thaddeus E. Kelly,Frank T. Saulsbury,Phillip F. Chance,Hans D. Ochs +9 more
TL;DR: Genetic evidence is presented that different mutations of the human gene FOXP3, the ortholog of the gene mutated in scurfy mice (Foxp3), causes IPEX syndrome.
Journal ArticleDOI
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Katarina Le Blanc,Ida Rasmusson,Berit Sundberg,Cecilia Götherström,Moustapha Hassan,Mehmet Uzunel,Olle Ringdén +6 more
TL;DR: It is postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo and are transplanted in a patient with severe treatment-resistant grade IV acute graft-versus-host disease of the gut and liver.